No. Regimens Level of Risk Gene Mutations Gene Fusion Treatment Method D21 MRD D28 MRD Current Condition
AML-1 CCLG-2019 High risk PTPN11 KMT2A-MLLT3, MLL-AF9 Chemotherapy + venetoclax Bone marrow no response - Died due to severe infection after chemotherapy
AML-2 CCLG-2015 High risk GATA2, WT1 NUP98-HoxA9 Chemotherapy + transplantation 9.36×10-3 2.609×10-3 Relapsed and died 3 years after transplantation
AML-3 CCLG-2019 High risk No No Chemotherapy + venetoclax + transplantation 4.67×10-2 7.72×10-2 Died after transplantation
AML-4 CCLG-2019 High risk No No Chemotherapy + venetoclax + transplantation - Negative In transplantation
AML-5 CCLG-2019 High risk IDH2, NRAS, WT1 No Chemotherapy + venetoclax + transplantation 6×10-4 9×10-4 One year after transplantation
AML-6 CCLG-2019 Intermediate risk IDH1, NPM1, PTPN11 Low-level FLT3-ITD Chemotherapy + venetoclax + gilteritinib Negative Negative In chemotherapy
AML-7 CCLG-2019 High risk No No Chemotherapy + venetoclax + transplantation One year after transplantation
AML-8 CCLG-2019 Standard risk No CBFβ-MYH11 Chemotherapy Negative Negative Drug withdrawal for three years
AML-9 CCLG-2019 High risk RUNX1, ASXL1, SETBP1, EZH2 No Chemotherapy + venetoclax + transplantation 1.44×10^e-2 1.83×10^e-2 One year after transplantation
AML-10 CCLG-2019 High risk No No Chemotherapy + transplantation 3.4×10-3 Two years after transplantation
AML-11 CCLG-2015 Standard risk PHF6 AML1-ETO Chemotherapy 2.694×10-3 4.3×10-4 Drug withdrawal for five years
AML-12 CCLG-2015 Intermediate risk PTPN11 No Chemotherapy 5.05×10-2 2.28×10-2 Gave up and died after chemotherapy
AML-13 CCLG-2015 High risk WT1 No Chemotherapy + transplantation Positive Six years after transplantation
AML-14 CCLG-2015 Standard risk TP53 AML1-ETO Chemotherapy 1.413×10-1 6.9×10-2 Drug withdrawal for six years
AML-15 CCLG-2015 High risk c-KIT,TP53 CBFβ-MYH11 Chemotherapy + transplantation 2.43×10^-3 2.04×10-3 Six years after transplantation
APL-1 APL-2016 Standard risk No PML-RARA Chemotherapy Negative 5.87×10-2 Drug withdrawal for three years